DaVita Inc. (NYSE:DVA - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $177.06, but opened at $154.00. DaVita shares last traded at $155.26, with a volume of 1,182,682 shares.
Analyst Ratings Changes
Separately, Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $162.80.
Read Our Latest Research Report on DVA
DaVita Stock Performance
The company has a fifty day moving average price of $161.41 and a two-hundred day moving average price of $157.91. The company has a market capitalization of $12.71 billion, a P/E ratio of 16.72, a PEG ratio of 0.84 and a beta of 0.94. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. Equities analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On DaVita
A number of institutional investors have recently modified their holdings of DVA. United Capital Financial Advisors LLC boosted its position in DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after acquiring an additional 62 shares during the last quarter. Freedom Investment Management Inc. grew its stake in DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares during the period. MML Investors Services LLC lifted its stake in DaVita by 1.3% in the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after buying an additional 68 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of DaVita by 8.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after acquiring an additional 68 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of DaVita by 1.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company's stock valued at $776,000 after acquiring an additional 70 shares in the last quarter. 90.12% of the stock is owned by institutional investors.
DaVita Company Profile
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.